Fondazione Italiana Linfomi - Ets
Clinical trials sponsored by Fondazione Italiana Linfomi - Ets, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Rare heart cancer under the microscope: italian study seeks answers Results expected Oct 2026 (estimated)
- Elderly lymphoma Patients' Well-Being under the microscope Results expected Dec 2026 (estimated)
- Scientists dig deeper into follicular lymphoma genes Results expected Dec 2026 (estimated)
- Italian study tracks Real-World use of zanubrutinib for rare blood cancer Results expected Dec 2026 (estimated)
- New combo aims to boost transplant success in Hodgkin's lymphoma Results expected Dec 2026 (estimated)
-
New pill shows promise for frail elderly lymphoma patients
Disease control Not yet recruitingThis phase 2 study tests pirtobrutinib, a daily oral drug, as a first treatment for elderly patients (70+) with mantle cell lymphoma who are considered unfit or frail. The goal is to see if the drug can control the cancer and delay progression. 56 participants will take the drug …
Phase 2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Elderly lymphoma patients may benefit from Geriatric-Guided support
Symptom relief Not yet recruitingThis study tests whether adding geriatric-guided care—including nutritional and physical therapy support—improves quality of life for elderly patients with diffuse large B-cell lymphoma. About 170 patients aged 70 and older who are unfit or frail will receive either this extra su…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Rare lymphoma study aims to unlock secrets of treatment success
Knowledge-focused Not yet recruitingThis study will gather information from 100 people with a rare type of lymphoma called systemic anaplastic large cell lymphoma (sALCL) who have been treated with a drug combination called BV-CHP. Researchers want to see how well the treatment works in real life and understand why…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Blood tests could reveal who benefits from Next-Gen lymphoma antibodies
Knowledge-focused Not yet recruitingThis observational study is looking at whether biological markers in blood, tumor tissue, and imaging scans can predict how well patients with B-cell non-Hodgkin lymphoma respond to treatment with novel monoclonal antibodies. Researchers will collect samples from about 1,000 adul…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Brain fog after lymphoma: study probes lasting cognitive effects of chemotherapy
Knowledge-focused Not yet recruitingThis study looks at thinking skills, memory, and quality of life in people who are 3 to 5 years past successful treatment for Hodgkin lymphoma or certain types of B-cell lymphoma. Participants take a series of tests and questionnaires once during a regular follow-up visit. The go…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New study to track brain health after CAR-T cancer treatment
Knowledge-focused Not yet recruitingThis study follows 100 adults with certain types of lymphoma who are receiving CAR-T cell therapy. Researchers will test memory, attention, and other thinking skills before treatment and at 6, 12, and 24 months after. The goal is to learn how CAR-T therapy affects brain function …
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC